CA2837926A1 - Scyllo - inositol for the treatment of behavioral and psychiatric disorders - Google Patents

Scyllo - inositol for the treatment of behavioral and psychiatric disorders Download PDF

Info

Publication number
CA2837926A1
CA2837926A1 CA2837926A CA2837926A CA2837926A1 CA 2837926 A1 CA2837926 A1 CA 2837926A1 CA 2837926 A CA2837926 A CA 2837926A CA 2837926 A CA2837926 A CA 2837926A CA 2837926 A1 CA2837926 A1 CA 2837926A1
Authority
CA
Canada
Prior art keywords
inositol
scyllo
dementia
patient
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837926A
Other languages
English (en)
French (fr)
Inventor
Susan ABUSHAKRA
Gerald CRANS
Jesse Cedarbaum
Ramon Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transition Therapeutics Ireland Ltd
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of CA2837926A1 publication Critical patent/CA2837926A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2837926A 2011-06-03 2012-06-04 Scyllo - inositol for the treatment of behavioral and psychiatric disorders Abandoned CA2837926A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161520031P 2011-06-03 2011-06-03
US61/520,031 2011-06-03
US201161541333P 2011-09-30 2011-09-30
US61/541,333 2011-09-30
US201261618680P 2012-03-31 2012-03-31
US61/618,680 2012-03-31
PCT/US2012/040789 WO2012173808A1 (en) 2011-06-03 2012-06-04 Scyllo-inositol for the treatment of behavioral and psychiatric disorders

Publications (1)

Publication Number Publication Date
CA2837926A1 true CA2837926A1 (en) 2012-12-20

Family

ID=46298680

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837926A Abandoned CA2837926A1 (en) 2011-06-03 2012-06-04 Scyllo - inositol for the treatment of behavioral and psychiatric disorders

Country Status (11)

Country Link
US (1) US20140243422A1 (enExample)
EP (1) EP2714050A1 (enExample)
JP (1) JP2014515408A (enExample)
KR (1) KR20140041670A (enExample)
CN (1) CN103906520A (enExample)
AU (1) AU2012271068A1 (enExample)
BR (1) BR112013031117A8 (enExample)
CA (1) CA2837926A1 (enExample)
IL (1) IL229658A0 (enExample)
RU (1) RU2013154699A (enExample)
WO (1) WO2012173808A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2014110277A1 (en) * 2013-01-09 2014-07-17 Elan Pharmaceuticals, Inc. Methods of treating developmental and personality disorders
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
GB2557471A (en) * 2015-06-30 2018-06-20 Jds Therapeutics Llc Arginine silicate inositol for improving cognitive function
WO2017029353A1 (en) * 2015-08-20 2017-02-23 Transition Therapeutics Ireland Limited Treatment of behaviors in dementia patients
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
EP3506895A4 (en) 2016-09-01 2020-04-15 JDS Therapeutics, LLC MAGNESIUM BIOTINATE COMPOSITIONS AND METHOD FOR USE
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
HRP20250882T1 (hr) * 2019-12-02 2025-09-26 Suven Life Sciences Limited Kombinacije masupirdina sa donepezilom ili memantinom za liječenje bihevioralnih i psiholoških simptoma kod pacijenata sa demencijom
MX2022006535A (es) * 2019-12-02 2022-09-09 Suven Life Sciences Ltd Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
CA3266641A1 (en) * 2022-09-07 2024-03-14 Eirgen Pharma, Ltd. SCYLLO-INOSITOL IN COMBINATION WITH IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
US7745671B2 (en) 2003-10-14 2010-06-29 Hokko Chemical Industry Co., Ltd. Method for producing scyllo-inositol
BRPI0708725A2 (pt) * 2006-03-09 2011-06-07 Waratah Pharmaceuticals Inc formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna
CN101505741A (zh) * 2006-03-09 2009-08-12 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂
EP2545023A4 (en) 2010-02-15 2017-04-12 Abbvie Inc. Process for the preparation of scyllo-inositol
US20150306043A1 (en) * 2012-09-28 2015-10-29 Transition Therapeutics Ireland Limited Combination treatments for bipolar disorders

Also Published As

Publication number Publication date
CN103906520A (zh) 2014-07-02
IL229658A0 (en) 2014-01-30
AU2012271068A1 (en) 2013-12-19
JP2014515408A (ja) 2014-06-30
US20140243422A1 (en) 2014-08-28
EP2714050A1 (en) 2014-04-09
WO2012173808A1 (en) 2012-12-20
BR112013031117A2 (pt) 2018-06-19
KR20140041670A (ko) 2014-04-04
RU2013154699A (ru) 2015-07-20
BR112013031117A8 (pt) 2018-08-14

Similar Documents

Publication Publication Date Title
US20140243422A1 (en) Methods of treating behavioral and psychiatric disorders
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
US8283336B2 (en) Unit dosage for brain health
AU2011203867B2 (en) Methods of providing weight loss therapy in patients with major depression
US20220362197A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US9486430B2 (en) Treatment of neurodegenerative disease
WO2020118142A1 (en) Ganaxolone for use in prophylaxis and treatment of pospartum depression
US20250017946A1 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
US20240285656A1 (en) Cannabidiol (cbd) and terpene formulation that increases restorative sleep in humans
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2018002937A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
Sarkar et al. Role of Nutraceuticals in the Prevention and Management of Degenerative Diseases
CN118613265A (zh) 用于治疗神经变性疾病的胆汁酸和苯基丁酸化合物的组合
Marsili et al. 31 Cerebellar Ataxia
Vgenopoulou et al. Melatonin levels in Alzheimer disease
Lazowski An Investigation of Sleep Architecture and Consequent Cognitive Changes in Olanzapine Treated Patients with Depression

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170606